829 related articles for article (PubMed ID: 31050774)
1. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.
Haslam A; Prasad V
JAMA Netw Open; 2019 May; 2(5):e192535. PubMed ID: 31050774
[TBL] [Abstract][Full Text] [Related]
2. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J; Chen EY; Prasad V
JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
5. Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018.
DeMartino PC; Miljkovic MD; Prasad V
JAMA Intern Med; 2021 Feb; 181(2):162-167. PubMed ID: 33165499
[TBL] [Abstract][Full Text] [Related]
6. Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020.
Haslam A; Kim MS; Prasad V
Ann Oncol; 2021 Jul; 32(7):926-932. PubMed ID: 33862157
[TBL] [Abstract][Full Text] [Related]
7. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Davis AA; Patel VG
J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
[TBL] [Abstract][Full Text] [Related]
8. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
9. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
Chen EY; Raghunathan V; Prasad V
JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
[TBL] [Abstract][Full Text] [Related]
10. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
[TBL] [Abstract][Full Text] [Related]
12. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs.
Haslam A; Gill J; Prasad V
JAMA Netw Open; 2020 Mar; 3(3):e200423. PubMed ID: 32150268
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
14. Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved.
Zhang SX; Fergusson D; Kimmelman J
J Natl Cancer Inst; 2020 Sep; 112(9):886-892. PubMed ID: 32239146
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.
Ben-Aharon O; Magnezi R; Leshno M; Goldstein DA
JAMA Oncol; 2018 Mar; 4(3):326-332. PubMed ID: 29285547
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration.
Liang F; Zhang S; Wang Q; Li W
BMC Cancer; 2020 Aug; 20(1):823. PubMed ID: 32867707
[TBL] [Abstract][Full Text] [Related]
18. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
[TBL] [Abstract][Full Text] [Related]
19. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021.
Benjamin DJ; Xu A; Lythgoe MP; Prasad V
JAMA Netw Open; 2022 Mar; 5(3):e222265. PubMed ID: 35289858
[TBL] [Abstract][Full Text] [Related]
20. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
Michaeli T; Jürges H; Michaeli DT
BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]